What Is Sauvagine? Definition and What Research Reports

Plain definition

Sauvagine is a 40-amino-acid peptide originally isolated from the skin secretion of a South American tree frog of the genus Phyllomedusa (the species name sauvagii is the source of the term). It is classified as a member of the corticotropin-releasing factor (CRF) peptide family, a group of structurally related neuropeptides that signal through class B G-protein-coupled receptors known as CRF1 and CRF2, as summarised in a review of corticotropin-releasing hormone receptors (PMID 12196108). In practice, the word appears in research papers as the name of a peptide reagent used to probe those receptors, not as the name of an approved medicine or a consumer product.

What class of molecule it is, and where it comes from

Sauvagine is a peptide — a short chain of amino acids — of amphibian origin. Amphibian skin secretions are a long-standing source of bioactive peptides in natural-products chemistry, and a 2020 review of kambô, the secretion of the Amazonian frog Phyllomedusa bicolor, described how such secretions contain families of peptides that act on mammalian receptors and discussed the safety questions raised by their ritual human use (PMID 32566126). Sauvagine is discussed in that same broad literature of frog-skin peptide chemistry.

Functionally, it sits in a family that spans a wide swathe of animal life. Mammals produce CRF and the urocortins; bony fish produce urotensin I; and researchers have even reported the molecular identification and cellular localisation of a CRH-type neuropeptide in an echinoderm, indicating that the signalling system is evolutionarily ancient (PMID 33965952).

The peptide family at a glance

How the term is used in peptide research

When the term appears in a methods section, it usually refers to a synthetic peptide applied to cells, tissue preparations or laboratory animals to activate CRF receptors so that a downstream response can be measured. Because the CRF system is organised around two receptor subtypes with different tissue distributions and different ligand preferences, much of the field's work involves separating CRF1 from CRF2 signalling, a distinction laid out in the receptor review cited above (PMID 12196108). Sauvagine is one of several family peptides referenced in that context.

Alongside agonist peptides, researchers develop small-molecule antagonists as pharmacological tools. A 2025 paper reported the pharmacological characterisation of M43, a novel thiazolo[4,5-d]pyrimidine analogue described as a CRF1 receptor antagonist (PMID 41008572), and a 2019 report described selective antagonism of the CRF1 receptor by a substituted pyrimidine (PMID 30980254). Studies of this kind are how the field assigns an observed effect to one receptor subtype rather than the other.

What the published literature reports

Feeding and appetite

A 2020 review of the CRF system across animals reported that CRF-family signalling suppresses feeding and examined the mechanisms proposed for that effect in different species (PMID 31935510). In a 2018 avian study, researchers reported that corticotrophin-releasing factor mediated vasoactive intestinal peptide-induced hypophagia and accompanying changes in plasma parameters (PMID 30138609). These findings concern the receptor system to which sauvagine belongs rather than sauvagine used as a therapy.

Gastrointestinal tissue

A 2023 study in murine colon reported that corticotropin-releasing factor receptor agonists decreased interstitial cells of Cajal, the pacemaker cells that help coordinate gut motility (PMID 36377810). The study was conducted in mouse tissue, and its authors framed the result as a mechanistic observation about CRF receptor activation in the gut wall.

Muscle cells and metabolism

In cultured C2C12 muscle cells, researchers reported that CRF type 2 receptors mediated the metabolic effects of ghrelin (PMID 23804489). That result is an example of how CRF2 signalling has been linked experimentally to energy handling in a cell model rather than in people.

Brain reward circuits

A 2003 neurochemistry study reported that dopamine-dependent responses to cocaine depended on corticotropin-releasing factor receptor subtypes (PMID 12614338). This line of work is one reason CRF receptor pharmacology has been studied in the context of stress and substance-use models.

Safety and adverse events: What Studies Report

The verified literature assembled here does not contain human safety trials of sauvagine, and no dosing information for sauvagine in humans is reported in these sources; consequently none is described on this page. The closest safety-relevant material concerns amphibian skin secretions more broadly: the 2020 kambô review discussed the composition of frog skin secretion used in ritual practice and the safety concerns raised about it in the published record (PMID 32566126). Preclinical reports such as the finding that CRF receptor agonists decreased interstitial cells of Cajal in mouse colon (PMID 36377810) describe biological consequences of receptor activation in animal tissue, which is not the same as a characterised human adverse-event profile. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or any substance discussed in the research literature.

Limits of the evidence

• Most findings are about the receptor system, not the peptide itself. Papers on CRF1 and CRF2 pharmacology describe a shared signalling pathway (PMID 12196108); results obtained with one family ligand do not automatically transfer to another.
• Species and model differences are large. The feeding literature spans fish, birds and mammals (PMID 31935510), and an avian hypophagia result (PMID 30138609) is not a human finding.
• Cell-culture results are mechanistic. The C2C12 work on CRF2 and ghrelin was performed in a myotube line (PMID 23804489).
• Tool compounds matter. Subtype assignments often rest on selective antagonists such as those characterised in 2019 and 2025 (PMID 30980254, PMID 41008572).

Related glossary terms

• Corticotropin-releasing factor (CRF/CRH) — the mammalian parent peptide of the family (PMID 12196108).
• CRF1 and CRF2 receptors — the two receptor subtypes targeted in this literature (PMID 12196108).
• Urocortins and urotensin I — other family members referenced in receptor pharmacology (PMID 12196108).
• CRH-type neuropeptide — the invertebrate counterpart identified in an echinoderm (PMID 33965952).

References

• Corticotropin-releasing hormone receptors (Biochemical Society Transactions, 2002)
• KAMBÔ: an Amazonian enigma (Journal of Venom Research, 2020)
• Molecular Identification and Cellular Localization of a Corticotropin-Releasing Hormone-Type Neuropeptide in an Echinoderm (Neuroendocrinology, 2023)
• The suppression effects of feeding and mechanisms in CRF system of animals (Gene, 2020)
• Corticotrophin-releasing factor mediates vasoactive intestinal peptide-induced hypophagia and changes in plasma parameters (Hormones and Behavior, 2018)
• Corticotropin-releasing factor receptor agonists decrease interstitial cells of Cajal in murine colon (Neurogastroenterology and Motility, 2023)
• CRF type 2 receptors mediate the metabolic effects of ghrelin in C2C12 cells (Obesity, 2014)
• Dopamine-dependent responses to cocaine depend on corticotropin-releasing factor receptor subtypes (Journal of Neurochemistry, 2003)
• Selective antagonism of CRF1 receptor by a substituted pyrimidine (Hormones, 2019)
• Pharmacological Characterization of the Novel CRF1 Receptor Antagonist, Thiazolo[4,5-d] Pyrimidine Analog, M43 (Biomolecules, 2025)